INVESTORS & MEDIA

Press Releases

Year

Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)

December 4, 2020

Acceptable Toler ability and Safety Profile in 27 Patients with No Graft versus Host Disease (GvHD), No Grade ≥ 3 Cytokine Release Syndrome (CRS) , and No Grade ≥ 3 Neurotoxicity (ICANS) PBCAR0191 Demonstrated Longest Durability of Response to 11 months in B-ALL PBCAR0191 with Enhanced...

Precision BioSciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

November 24, 2020

DURHAM, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS ® genome editing platform, today announced that its Chief Scientific Officer, Derek Jantz, Ph.D., will...

Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement

November 20, 2020

Research collaboration using ARCUS genome editing technology will initially include three gene targets, with right to select three additional gene targets; lead program focused on Duchenne Muscular Dystrophy Precision will receive $100 million cash upfront and an equity investment by Lilly of $35...

Precision BioSciences Reports Third Quarter 2020 Financial Results and Provides Business Update

November 10, 2020

Expanded allogeneic CAR T development collaboration with Servier to include four new programs targeting hematological and solid tumors Advanced CAR T clinical pipeline, including a clinical collaboration with SpringWorks to evaluate PBCAR269A in combination with nirogacestat Prevailed in U.S....

Precision BioSciences to Report Third Quarter 2020 Financial Results on November 10, 2020

November 3, 2020

DURHAM, N.C., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS ® genome editing platform, today announced that it will publish financial results for the third quarter...

Precision BioSciences Announces U.S. Patent Trial and Appeal Board Upholds Allogeneic CAR T Patents

October 15, 2020

PTAB Rules in Favor of Precision BioSciences in Two Patent Interference Proceedings DURHAM, N.C., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ®...

Precision BioSciences Appoints Alex Kelly as Chief Corporate Affairs Officer

October 14, 2020

DURHAM, N.C., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today announced that Alex Kelly has been appointed to the...

Precision BioSciences to Present at Upcoming Virtual Investor Conferences in October

September 28, 2020

DURHAM, N.C., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today announced its participation in the following upcoming...

Elo Life Systems Appoints Food and Beverage Industry Technology Leader Alec Hayes as Vice President of Technology and Products

September 21, 2020

Durham, N.C., September 21, 2020 – Elo Life Systems, a food and agriculture company with a mission to improve human health and wellness, today announced that Alec Hayes, Ph.D., has joined Elo Life Systems as Vice President of Technology and Products. In his role, Alec will be responsible for Elo’s...

Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma

September 21, 2020

Increasing BCMA Surface Expression and Reduced Soluble BCMA Levels with Gamma Secretase Inhibitor Nirogacestat May Enhance Clinical Benefit in Combination with PBCAR269A, an Allogeneic BCMA-Targeted CAR T Cell Product DURHAM, N.C. and STAMFORD, Conn., Sept....

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 30

INVESTORS & MEDIA

Overview
Corporate Governance
Press Releases
Events & Presentations
Stock Information
Analyst Coverage
SEC Filings
Corporate Deck
2019 Annual Report
Investor FAQs

Investor Tools

Print Page
Email Page
Email Alerts
Document Request
Contact IR
RSS Feeds

INVESTORS & MEDIA

Press Releases

Press Releases

INVESTORS & MEDIA

Investor Tools

Contact Info

919.314.5512

About Us

Quick Links

Legal